<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116385">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588028</url>
  </required_header>
  <id_info>
    <org_study_id>AF002JG</org_study_id>
    <secondary_id>NP28761</secondary_id>
    <nct_id>NCT01588028</nct_id>
  </id_info>
  <brief_title>A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      CH5424802 is a newly invented, selective oral ALK inhibitor. In the Phase I portion, the
      goal is to determine the following: dose limiting toxicity, the maximum tolerated dose,
      pharmacokinetic (PK) parameters, and the recommended dose.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Dose limiting toxicity</measure>
    <time_frame>Phase I: April 2012 to September 2014</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Tumor regression effect, PK parameters</measure>
    <time_frame>Phase I: April 2012 to September 2014</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>ALK-Rearranged Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>locally advanced or metastatic ALK-positive NSCLC patients who have failed crizotinib treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CH5424802</intervention_name>
    <description>Oral capsules taken twice daily</description>
    <arm_group_label>phase 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG performance status =&lt; 2

          -  Confirmed of ALK-positive NSCLC by FDA approved kit

          -  NSCLC that has failed crizotinib treatment for Phase I

          -  Measurable disease defined by RECIST 1.1

          -  Adequate hematologic, hepatic, renal function

        Exclusion Criteria:

          -  Prior therapy with an ALK inhibitor other than crizotinib

          -  Brain metastases, which are symptomatic and/or requiring treatment

          -  History of serious cardiac dysfunction

          -  Clinically significant gastrointestinal abnormality that would affect the absorption
             of drug

          -  Pregnant or a lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 16, 2014</lastchanged_date>
  <firstreceived_date>April 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
